Hang Xi

TL;DR: A novel flow-cytometric gating method was established to define pyrotosis (Annexin V(-)/Propidium iodide(+) and termed caspase-1 responsive pyroptosis and apoptosis as pyrop-apoptosis.

TL;DR: It is demonstrated for the first time that early hyperlipidemia promotes EC activation before monocyte recruitment via a caspase-1–sirtuin 1–activator protein-1 pathway, which provides an important insight into the development of novel therapeutics for blocking caspasing-1 activation as early intervention of metabolic cardiovascular diseases and inflammations.

TL;DR: A new paradigm that most nuclear receptors are anti-inflammatory homeostasis-associated molecular pattern receptors (HAMPRs) is proposed to provide a novel insight on NRs as therapeutic targets in metabolic diseases, inflammations, and malignancies.

TL;DR: It is suggested that IL-35 is an attractive novel therapeutic reagent for sepsis and cardiovascular diseases because it inhibits vascular response in acute inflammation and attenuates LPS-induced secretion of proinflammatory cytokines/chemokines.

TL;DR: Inhibition of caspase-1 improves VEGFR-2 signaling, tube formation, and blood perfusion in ischemic tissues, and demonstrates for the first time that inhibition of proatherogenic casp enzyme-1 activation in ECs improves angiogenesis and the prognosis of ischemia.